CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply

被引：1
作者：
Brauch, Hiltrud [1 ,2 ]
Schwab, Matthias [1 ,2 ,3 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Univ Hosp Tuebingen, Dept Clin Pharmacol, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2014年 / 78卷 / 02期
关键词：
WOMEN;
D O I：
10.1111/bcp.12330
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：433 / 434
页数：2
相关论文
共 11 条
[1]  
Ahern TP, 2012, CLIN EPIDEMIOL, V2, P241
[2]   CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer [J].
Berry, Donald .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17) :1267-1269
[3]   Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer [J].
Brauch, Hiltrud ;
Schwab, Matthias .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (04) :695-703
[4]   Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters [J].
Brauch, Hiltrud ;
Schroth, Werner ;
Goetz, Matthew P. ;
Muerdter, Thomas E. ;
Winter, Stefan ;
Ingle, James N. ;
Schwab, Matthias ;
Eichelbaum, Michel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :176-180
[5]   CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer [J].
Damkier, Per .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) :431-432
[6]   Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA [J].
Rae, James M. ;
Regan, Meredith M. ;
Thibert, Jacklyn N. ;
Gersch, Christina ;
Thomas, Dafydd ;
Leyland-Jones, Brian ;
Viale, Giuseppe ;
Pusztai, Lajos ;
Hayes, Daniel F. ;
Skaar, Todd ;
Van Poznak, Catherine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17) :1332-1334
[7]   CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J].
Rae, James M. ;
Drury, Suzy ;
Hayes, Daniel F. ;
Stearns, Vered ;
Thibert, Jacklyn N. ;
Haynes, Ben P. ;
Salter, Janine ;
Sestak, Ivana ;
Cuzick, Jack ;
Dowsett, Mitch .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :452-460
[8]   CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality [J].
Ratain, M. J. ;
Nakamura, Y. ;
Cox, N. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) :184-186
[9]   CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [J].
Regan, Meredith M. ;
Leyland-Jones, Brian ;
Bouzyk, Mark ;
Pagani, Olivia ;
Tang, Weining ;
Kammler, Roswitha ;
Dell'Orto, Patrizia ;
Biasi, Maria Olivia ;
Thuerlimann, Beat ;
Lyng, Maria B. ;
Ditzel, Henrik J. ;
Neven, Patrick ;
Debled, Marc ;
Maibach, Rudolf ;
Price, Karen N. ;
Gelber, Richard D. ;
Coates, Alan S. ;
Goldhirsch, Aron ;
Rae, James M. ;
Viale, Giuseppe .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :441-451
[10]   Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen [J].
Schroth, Werner ;
Goetz, Matthew P. ;
Hamann, Ute ;
Fasching, Peter A. ;
Schmidt, Marcus ;
Winter, Stefan ;
Fritz, Peter ;
Simon, Wolfgang ;
Suman, Vera J. ;
Ames, Matthew M. ;
Safgren, Stephanie L. ;
Kuffel, Mary J. ;
Ulmer, Hans Ulrich ;
Bolaender, Julia ;
Strick, Reiner ;
Beckmann, Matthias W. ;
Koelbl, Heinz ;
Weinshilboum, Richard M. ;
Ingle, James N. ;
Eichelbaum, Michel ;
Schwab, Matthias ;
Brauch, Hiltrud .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (13) :1429-1436
12